Department of Internal Medicine I, University Hospital Dresden, Technical University Dresden, Dresden, Germany.
Altona Children's Hospital, Hamburg, Germany.
Blood. 2024 Oct 3;144(14):1532-1542. doi: 10.1182/blood.2024024342.
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy and birth rates in a contemporary cohort, we conducted a national multicenter study using data from the German Transplant Registry, focusing on adult women aged 18 to 40 years who underwent alloHCT between 2003 and 2018. Of 2654 women who underwent transplantation, 50 women experienced 74 pregnancies, occurring at a median of 4.7 years after transplant. Fifty-seven of these resulted in live births (77%). The annual first birth rate among HCT recipients was 0.45%, which is >6 times lower than in the general population. The probability of a live birth 10 years after HCT was 3.4%. Factors associated with an increased likelihood of pregnancy were younger age at alloHCT, nonmalignant transplant indications, no total body irradiation or a cumulative dose of <8 Gy, and nonmyeloablative/reduced-intensity conditioning. Notably, 72% of pregnancies occurred spontaneously, with assisted reproductive technologies used in the remaining cases. Preterm delivery and low birth weight were more common than in the general population. This study represents the largest data set reporting pregnancies in a cohort of adult female alloHCT recipients. Our findings underscore a meaningful chance of pregnancy in alloHCT recipients. Assisted reproductive technologies techniques are important and funding should be made available. However, the potential for spontaneous pregnancies should not be underestimated, and patients should be informed of the possibility of unexpected pregnancy despite reduced fertility. Further research is warranted to understand the impact of conditioning decisions on fertility preservation.
异基因造血细胞移植(alloHCT)后的长期生存率提高,使得年轻癌症幸存者的生育计划成为一个重要话题。然而,与治疗相关的不孕风险带来了挑战。为了评估当代队列中的妊娠和出生率,我们使用德国移植登记处的数据进行了一项全国多中心研究,重点关注 18 至 40 岁接受 alloHCT 的成年女性,这些患者于 2003 年至 2018 年期间接受移植。在 2654 名接受移植的女性中,有 50 名女性经历了 74 次妊娠,移植后中位时间为 4.7 年。其中 57 次妊娠导致活产(77%)。HCT 受者的首次年出生率为 0.45%,比一般人群低 6 倍以上。HCT 后 10 年活产的概率为 3.4%。与妊娠可能性增加相关的因素包括 alloHCT 时年龄较小、非恶性移植指征、未接受全身照射或累积剂量<8Gy 以及非清髓性/减强度预处理。值得注意的是,72%的妊娠是自然发生的,其余病例使用了辅助生殖技术。早产和低出生体重比一般人群更为常见。本研究代表了报告成年 alloHCT 受者队列中妊娠情况的最大数据集。我们的研究结果强调了 alloHCT 受者妊娠的重要机会。辅助生殖技术是重要的,应该提供资金支持。然而,不应低估自然妊娠的可能性,并且尽管生育能力降低,也应告知患者意外妊娠的可能性。需要进一步研究以了解调理决策对生育力保存的影响。